Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mankind Pharma Ltd (MNKI)
The Mankind Pharma share price today is 2,438.00, view BO MNKI stock exchange data. Track the latest Mankind Pharma share price with real-time updates on MNKI stock performance including market cap, day range, 52-week range and dividend yield. Access MNKI charts, earnings dates and analyst estimates to support your investment decisions.
2,438.00
-1.00(-0.04%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,429.00
2,482.15
52 wk Range
1,909.90
2,670.00
MNKI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,429.002,482.15
52 wk Range
1,909.902,670.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.04%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.04%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MNKI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Mankind Pharma Ltd Earnings Call Summary for Q1/2027
- Mankind Pharma Q1 FY2027 revenue rose 12.9% YoY to INR 4,031 crore; PAT jumped 29.1% to INR 574 crore with EPS of INR 13.7, beating estimates.
- EBITDA margin expanded 250 bps to 26.3%; chronic portfolio grew 15.8% while acute therapies recovered 10.9%, shifting mix toward stable growth.
- Net debt fell to INR 3,377 crore (0.9x EBITDA); company on track to repay acquisition debt by FY2028 amid improved operating leverage.
- Management maintained FY2027 guidance: double-digit growth, EBITDA margin of 25.5%-26.5%, though warned of commodity and FX pressure on margins.
- Stock dipped 0.6% post-results; risks include higher tax rate after Sikkim exemption expiry, inventory build, and elevated valuation multiples.
Last Updated: 30-07-2026, 08:08 pm
Read Full TranscriptEarnings
Latest Release
30-07-2026
EPS / Forecast
13.80 / 13.12
Revenue / Forecast
40.31B / 39.79B
Compare MNKI to Peers and Sector
Metrics to compare | MNKI | Peers Peers - average of corresponding metrics from companies closely matching MNKI: AUROPHARMA, ALKEM, GLENMARK, AJANTPHARM, ZYDUSLIFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKIPeersSector |
|---|---|---|---|---|
P/E Ratio | 49.7x | 35.1x | −0.4x | |
PEG Ratio | 7.67 | 1.94 | 0.00 | |
Price/Book | 6.2x | 5.5x | 2.6x | |
Price / LTM Sales | 6.9x | 4.6x | 3.1x | |
Upside (Analyst Target) | 16.9% | 11.0% | 48.5% | |
Fair Value Upside | Unlock | 3.4% | 5.8% | Unlock |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Mankind Pharma (MNKI) Share Price Today?
The Mankind Pharma share price today is 2,438.00.
What is the current Mankind Pharma (MNKI) share price and day range?
As of 10-08-2026, the Mankind Pharma share price is 2,438.00, with a previous close of 2,439.00. The share price has ranged from 2,429.00 to 2,482.15 today, while the 52-week range spans from 1,909.90 to 2,670.00.
What Is the Mankind Pharma Market Cap?
As of today, Mankind Pharma market cap is 1.01T.
Does Mankind Pharma Pay Dividends? What's The Current Dividend Yield?
The Mankind Pharma dividend yield is 0.04%.
What Is Mankind Pharma's Earnings Per Share (TTM)?
The Mankind Pharma EPS (TTM) is 49.42.
When Is the Next Mankind Pharma Earnings Date?
Mankind Pharma will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is MNKI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Mankind Pharma Trade On?
Mankind Pharma is listed and trades on the Bombay Stock Exchange.
What Is the Stock Symbol for Mankind Pharma?
The stock symbol for Mankind Pharma is "MNKI."
How Many Times Has Mankind Pharma Stock Split?
Mankind Pharma has split 0 times.
How Many Employees Does Mankind Pharma Have?
Mankind Pharma has 20451 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.